NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA,  AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES
DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS
ANNOUNCEMENT.

Reference is made to the stock exchange announcement published by NEXT
Biometrics Group ASA (the "Company") earlier today, on 18 March 2026, regarding
a contemplated partially underwritten rights issue in the Company, raising gross
proceeds of up to NOK 50 million (the "Rights Issue"). Key information relating
to the Rights Issue is set out below.

Date on which the terms and conditions of the preferential Rights Issue were
announced: 18 March 2026.

Last day including rights: on or about 20 May 2026.

Ex-date: on or about 21 May 2026.

Record Date: on or about 22 May 2026 (assuming normal T+2 settlement).

Date of approval: on or about 20 May 2026.

Maximum number of new shares to be issued in the Rights Issue: 50,000,000,
subject to the completion of the reverse share split in the ratio of 10:1 (the
"Reverse Share Split") to be resolved by the Company's extraordinary general
meeting to be held 7 April 2026 (the "EGM").

Subscription price: NOK 0.10 per new share, however such that the subscription
price per new share shall be adjusted following completion of, and subject to
the EGM having resolved, the Reverse Share Split, resulting in a subscription
price of NOK 1.

Ratio preferential rights: To be announced following the Rights Issue having
been resolved.

Subscription ratio: 1:1 (number of new shares in the Company per subscription
right).

Manager: Arctic Securities AS.

Will the rights be listed: Yes, the Company will apply for listing of the
subscription rights on Euronext Oslo Børs. 

ISIN for the preferential rights: To be announced when clarified. 

Other information: Reference is made to the stock exchange announcements
published by the Company earlier today, on 18 March 2026. Completion of the
Rights Issue is subject to, inter alia, (i) the EGM having resolved the Reverse
Share Split and a share capital decrease by the reduction of the nominal value
of the Company's shares (the "Share Capital Reduction"), (ii) the Share Capital
Reduction having been completed following expiry of a six-week creditor notice
period under Section 12-5 of the Norwegian Public Limited Liability Companies
Act, (iii) the annual general meeting of the Company to be held on or about 20
May 2026 (the "AGM") having resolved the Rights Issue, and (iv) the Financial
Supervisory Authority of Norway having approved, and the Company having
published, the a prospectus. The notice of the EGM was published on 17 March
2026, while the notice of the AGM will be published in a separate stock exchange
announcement three weeks prior to the date of the AGM.

For further information, please contact:
Ulf Ritsvall (CEO), ulf.ritsvall@nextbiometrics.com 
Eirik Underthun (CFO), eirik.underthun@nextbiometrics.com

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act. 

IMPORTANT INFORMATION

This announcement is not and does not form a part of any offer to sell, or a
solicitation of an offer to purchase, any securities of the Company. Copies of
this announcement are not being made and may not be distributed or sent into any
jurisdiction in which such distribution would be unlawful or would require
registration or other measures.

The securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the "Securities
Act"), and accordingly may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements of
the Securities Act and in accordance with applicable U.S. state securities laws.
The Company does not intend to register any part of the offering in the United
States or to conduct a public offering of securities in the United States. Any
sale in the United States of the securities mentioned in this announcement will
be made solely to "qualified institutional buyers" as defined in Rule 144A under
the Securities Act.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The expression "Prospectus
Regulation" means Regulation (EU) 2017/1129 as amended (together with any
applicable implementing measures in any Member State.

This communication is only being distributed to and is only directed at persons
in the United Kingdom that who fall within the definition of "investment
professionals" in Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net
worth entities falling within Article 49(2)(a) to (d) of the Order